The finding that MMR-deficiency does not alter 5-fluorouracil cytotoxicity in a p53-deficient setting may be of clinical interest for the treatment of colorectal cancer, despite the previously reported in vitro association of MMR with resistance to 5-fluorouracil in p53-proficient cells (Carethers et al, 1999). Here, TP53 is linked to colorectal cancer.